18 October 2019 - - US-based health intelligence company Sema4 has launched Expanded Carrier Screen with Personalized Residual Risk, a carrier screening option, to provide physicians and their patients with enhanced risk assessment analysis designed to inform family planning decisions, the company said.

Sema4 also announced it will soon utilize exome sequencing for the majority of genetic tests offered by the company.

This new exome testing platform was internally developed by Sema4's industry-leading clinicians and scientists, and includes thousands of genes identified by medical experts as clinically relevant and actionable.

All of Sema4's carrier screening panels, from single gene to 502 genes, will now include Personalized Residual Risk analysis of patient-specific ancestry markers to improve the accuracy and reliability of the results.

The next version of Sema4's expanded carrier screen, delivered via exome sequencing, will include thousands of genes deemed clinically actionable.

DNA-based carrier screening is recommended by The American College of Obstetricians and Gynecologists to help guide family planning for all women who are pregnant or planning for pregnancy.

It is a valuable tool enabling prospective parents to determine their risk of passing certain diseases or disorders on to their children.

Sema4 is a patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease.

Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualised health trajectories, starting in the areas of reproductive health and oncology.

Centrellis, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.